GlaxoSmithKline (GSK) is working to fight a contagious illness called respiratory syncytial virus (RSV), which can make people sick like the flu. This disease is especially risky for older adults. GSK has a vaccine called Arexvy, which was first allowed for people who are 60 years and older. Now, they have found that this vaccine may also help people who are 50 to 59 years old, especially if they have health problems like lung or heart issues or diabetes. GSK wants to tell the U.S. Food and Drug Administration (FDA) about these results so that more people can get the vaccine. Right now, only people who are 60 and older can get it.

GSK conducted a Phase 3 trial to test the vaccine on people aged 50–59 with health issues. Initial results are positive and awaiting expert review, and GSK aims to present the final results at a medical conference and in a reputable journal. Sharing with the FDA and regulators in 2024 is crucial because RSV can lead to hospitalizations and deaths, particularly in older individuals. The vaccine’s broader use could greatly improve public health.